This transaction
Transaction (acquisition)A Japan-based pharmaceutical company focused on rheumatology, orthopedics, pain management, and contract manufacturing services. The company sells a broad range of products centered on specialty pharmaceuticals and has manufacturing and sales operations serving healthcare providers nationwide.
The transaction is expected to significantly expand the scale of GNI Group's business and serve as a transformative transaction that accelerates sales growth.
| Item | Details |
|---|---|
| Transaction name | Transaction (acquisition) |
| Counterparty name | Blackstone, Toho Holdings Co., Ltd., Hisamitsu Pharmaceutical |
| Name of the Subject Company | あゆみ製薬ホールディングス株式会社 |
| Business Description of the Subject Company | A Japan-based pharmaceutical company focused on rheumatology, orthopedics, pain management, and contract manufacturing services. The company sells a broad range of products centered on specialty pharmaceuticals and has manufacturing and sales operations serving healthcare providers nationwide. |
| Location of the Subject Company | Japan |
| Net Sales of the Subject Company | Approximately ¥38.5 billion (fiscal year ending March 2026) |
| Operating Profit of the Subject Company | Approximately ¥6.2 billion (fiscal year ending March 2026) |
| Acquisition price | Approximately ¥44.8 billion (the valuation of Ayumi Pharmaceutical Holdings in the transaction) |
| Number of shares acquired | All shares (number of shares and voting rights: Not disclosed) |
| Impact on Business Performance | The transaction is expected to significantly expand the scale of GNI Group's business and serve as a transformative transaction that accelerates sales growth. |
| Execution Date / Effective Date | The company is expected to become a wholly owned subsidiary upon completion of the transaction (specific date: Not disclosed) |
| Management structure after acquisition | Following integration, the organization is expected to focus on 5 major therapeutic areas: fibrosis, pain management, rheumatology, oncology, and orthopedics. |
Items this document does not state (20)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The transaction will incorporate Ayumi Pharmaceutical's domestic sales infrastructure, customer base, and products in the pain management, rheumatology, and orthopedics fields, expanding GNI Group's sales platform in Japan. Through this, the company aims to strengthen the introduction of overseas pharmaceuticals and biosimilars into Japan, sales growth, its earnings base, and financial stability.